Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid’s Big Fat Charity Pub Quiz

Last week Lucid SPIRIT held the first ever Lucid Big Fat Charity Pub Quiz to raise money for our charity partner, Wycombe Homeless Connection (WHC).There were fabulous prizes to be...

Hannah – Celebrating Ten Magical Years at Lucid Group

Given that Lucid Group is only 11 years old itself, it’s a special occasion for the company to recognise significant Lucid anniversaries, especially for those with a decade of service...

It’s graduation day for Lucid’s inaugural intake of their Futures Academy

Lucid’s Futures Academy programme has come to an end for its inaugural set of graduates. The programme itself kick-started with an intensive 8-week training course back in October last year...

Lucid strengthens their medical writing team with new hires

Leading Edge, part of the Lucid Group family of companies, are set to create more magical programmes for their clients and patients by strengthening their talented medical writing team with...

Lucid limbers up for second annual sports day

Back for its second year running, yesterday Lucid held their annual sports day. This year, everyone got together with the goal to raise money for Wycombe Homeless Connection (WHC) –...

Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications

In this month’s Smart Thinking blog on PM.Live.com Amy Jackson, Editorial Director at Lucid Group discusses the need for ongoing professional development in strategic medical communications.Amy discusses how medical communications...

Making a Difference – The Future of Pharma

On a global scale, pharma is one of the least-trusted industries. And this is despite the fact that pharma contributes more than £30 BN each year to the UK economy,...

Lighthouse Medical Communications US makes the list of finalists for the 2018 PM360 Trailblalzer Awards

Lighthouse Medical Communications US, part of the award-winning Lucid Group of companies, is delighted to announce that their ACT on Anemia campaign, developed in collaboration with the American Kidney Fund,...

Pitch Perfect

What makes a perfect pitch? This week’s Thirsty Thursday – hosted by Louise Verrall, a managing director at Lucid Partners – was all about just that.Louise started her session with an involved...

Wycombe Homeless Connection and Lucid SPIRIT: a partnership with a difference

Earlier this year the Lucid charity working group, Lucid SPIRIT, was founded. The entire Lucid family was immediately on board and all voted to choose Wycombe Homeless Connection (WHC) as their...